When does docetaxel (FDA) exclusivity end?
Docetaxel’s FDA exclusivity date depends on which specific FDA “docetaxel” product and approval (e.g., the original reference product vs. later line extensions, new strengths, or reformulations) you mean. FDA exclusivity is granted per marketing application and product—not for the single generic drug name alone—so the exclusivity end date will vary by NDA/BLA.
How can I find the exact docetaxel FDA exclusivity date for my product?
To get the correct exclusivity end date, you need the exact FDA application record:
- the NDA/BLA number
- the product name/strength/manufacturer (the “reference listed drug” if applicable)
With the NDA/BLA number, you can check the FDA Drugs@FDA listing and the FDA Orange Book exclusivity data for that specific product to see the exclusivity type (for example, 3-year new clinical investigation exclusivity, 7-year approval exclusivity, etc.) and the expiration date.
Does “docetaxel exclusivity” mean patent protection or FDA exclusivity?
People often mix these two timelines:
- FDA exclusivity (a regulatory marketing-rights protection) is tied to the NDA approval and can expire even if patents still exist.
- Patent protection is separate and may extend beyond FDA exclusivity.
To map both, you typically cross-check:
- Orange Book exclusivity dates (FDA)
- listed patents and their expiration dates (patents)
Who has docetaxel exclusivity and why it can differ?
Docetaxel is widely marketed in multiple formulations over time. Later approvals (such as formulation changes or new strengths) can bring their own exclusivity windows, so the “exclusivity date” you’re looking for is usually tied to the specific NDA/BLA that covers the product you care about.
Where DrugPatentWatch can help
DrugPatentWatch tracks patent and exclusivity-related information for branded medicines and can be a useful starting point to identify the relevant protection landscape for docetaxel and specific products. You can search there for “docetaxel” and then verify the exact exclusivity end date against the FDA Orange Book entry for the specific product. [1]
---
Sources
- DrugPatentWatch – Docetaxel search